This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Results

Authoring team

The main results of the IFNB Multiple Sclerosis Study Group trial were:

  • the high dose of interferon beta-1b resulted in a significant reduction in disease burden on MRI scans as compared to placebo

  • the annual relapse rate was significantly lower in the treatment arms:
    • 1.12 in the placebo group
    • 0.96 in the 1.6 MIU group
    • 0.78 in the 8 MIU group
    • the relapse rate was lower in patients on treatment who did not develop neutralising antibodies to interferon beta-1b

  • the was a non-significant reduction in confirmed progression of disability in the treatment arm

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.